Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
The latest announcement is out from Baxter International ( (BAX) ).
Effective for the quarter ended June 30, 2026, Baxter International reorganized its reporting structure into two segments, Medical Products & Therapies and Healthcare Systems & Technologies, folding its former Pharmaceuticals segment into the Infusion Therapies & Platforms division and reallocating certain manufacturing-related sales to better align decision-making, cost structure and performance assessment. The company also revised its corporate cost allocation approach so some shared expenses remain unallocated and published unaudited recast segment and product category financial data for 2024–2025 and early 2026, along with non-GAAP operational and organic sales growth metrics, to enhance comparability and give investors a clearer view of underlying sales trends amid portfolio and geographic shifts such as its exit from IV solutions in China and activity under the Kidney Care manufacturing and supply agreement.
The most recent analyst rating on (BAX) stock is a Buy
with a $24.00 price target.
To see the full list of analyst forecasts on Baxter International stock,
see the BAX Stock Forecast page.
Spark’s Take on BAX Stock
According to Spark, TipRanks’ AI Analyst, BAX is a Neutral.
The score is held back primarily by weak profitability and a moderately levered balance sheet despite solid and improving cash generation. Technicals also remain soft with the stock below key long-term averages and a negative MACD. Offsetting these factors, management reiterated guidance and outlined a second-half recovery plan, while the dividend offers modest support even though the negative P/E reflects ongoing losses.
To see Spark’s full report on BAX stock,
click here.
More about Baxter International
Baxter International Inc. is a global medical products company serving hospitals and other healthcare providers, with a portfolio that includes sterile intravenous (IV) solutions, infusion systems, administration sets, parenteral nutrition therapies, specialty injectable pharmaceuticals, inhaled anesthesia and drug compounding services. It also offers advanced surgery products such as hemostats, sealants and adhesion prevention solutions, alongside connected care technologies including smart beds, patient monitoring systems, respiratory health devices and operating room integration tools for front-line clinical environments.
Average Trading Volume: 7,144,512
Technical Sentiment Signal: Sell
Current Market Cap: $11.66B
For detailed information about BAX stock, go to TipRanks’ Stock Analysis page.